超声引导下髂腰肌滑囊注射治疗全髋关节置换术后髂腰肌滑囊炎
回顾性分析42例全髋关节置换术后髂腰肌肌腱炎接受超声引导下皮质类固醇注射的患者,无髋臼杯前缘突出者成功率高,有突出者部分需髋臼翻修;总体翻修率11.9%,作者认为该注射安全有效。
要点
- 无髋臼杯前缘突出的22例中,4例(18.2%)末次随访仍有腹股沟疼痛,3例接受第二次注射后疼痛均缓解。
- 有前缘突出的20例中,5例因注射仅暂时缓解疼痛而接受髋臼翻修,翻修后疼痛均缓解。
- 总体腹股沟疼痛缓解率78.6%,总体翻修率11.9%。
核心结论
- 队列中78.6%的患者腹股沟疼痛缓解,但无髋臼杯前缘突出者成功率更高。
- 总体翻修率为11.9%。
- 超声引导下皮质类固醇注射在原发性全髋关节置换术后髂腰肌肌腱炎的诊断和治疗中似乎安全有效。
研究设计与样本
- 回顾性研究,纳入2009年至2020年单中心接受超声引导下皮质类固醇注射治疗原发性全髋关节置换术后髂腰肌肌腱炎的42例患者。
- 通过交叉侧位X线片(36例)或计算机断层扫描(6例)评估是否存在髋臼杯前缘突出。
- 结局包括再手术、末次随访腹股沟疼痛、额外滑囊内注射和Harris髋关节评分(HHS),随访至少1年。
- 采用描述性统计和注射前后HHS的单变量比较,alpha<0.05。
- 证据等级:Level IV,治疗性研究。
主要发现
- 无髋臼杯前缘突出的22例患者中,4例(18.2%)在超声引导下皮质类固醇注射后平均40个月(范围14-94个月)随访时仍有腹股沟疼痛;3例接受第二次注射,末次随访均无腹股沟疼痛;无患者需要髋臼翻修;平均HHS从74分(范围52-94分)改善至末次随访91分(范围76-100分;P<.001)。
- 有髋臼杯前缘突出的20例患者中,5例在注射仅暂时缓解疼痛后接受髋臼翻修,翻修后平均43个月(范围12-60个月)随访时腹股沟疼痛均缓解;其余15例中5例在平均35个月(范围12-83个月)随访时仍有腹股沟疼痛;平均HHS从注射前69分(范围50-96分)改善至末次随访81分(范围56-98分;P=.007)。
关键数值与推荐
- 无髋臼杯前缘突出者:注射后平均40个月随访时腹股沟疼痛持续率18.2%(4/22)。
- 有髋臼杯前缘突出者:5/20例接受髋臼翻修。
- 总体腹股沟疼痛缓解率78.6%,总体翻修率11.9%。
- 无突出组HHS从74分改善至91分(P<.001);有突出组HHS从69分改善至81分(P=.007)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Iliopsoas tendonitis can cause persistent pain after total hip arthroplasty (THA). Nonoperative management of iliopsoas tendonitis includes anti-inflammatory drugs and image-guided corticosteroid injections. This study evaluated the efficacy of ultrasound-guided corticosteroid injections (US-CSIs) for iliopsoas tendonitis following THA. METHODS: We retrospectively reviewed 42 patients who received an US-CSI for iliopsoas tendonitis after primary THA between 2009 and 2020 at a single institution. Outcomes including reoperation, groin pain at last follow-up, additional intrabursal injection, and Harris Hip Score (HHS) were evaluated at a minimum of 1 year. Cross-table lateral radiographs (36 patients) or computed tomography scans (6 patients) were reviewed to determine if anterior cup overhang was present, indicating a mechanical etiology of iliopsoas tendonitis. Descriptive statistics and univariate comparison of HHS preinjection and postinjection were performed, with alpha < 0.05. RESULTS: Among the 22 patients who did not have cup overhang, four (18.2%) had persistent groin pain at mean follow-up of 40 months (range, 14-94) after US-CSI. Three patients had a second injection; none had groin pain at most recent follow-up. No patients required acetabular revision. Mean HHS improved from 74 points (range, 52-94 points) to 91 points (range, 76-100 points; P < .001) at last follow-up. Among the 20 patients who had anterior cup overhang, five underwent acetabular revision after only temporary pain relief from injection. Groin pain was resolved in all revised patients at mean follow-up of 43 months (range, 12-60) after revision. Of the remaining 15 patients, five had persistent groin pain at mean follow-up of 35 months (range, 12-83). Mean HHS improved from 69 points (range, 50-96 points) preinjection to 81 (range, 56-98 points; P = .007) at last follow-up. CONCLUSION: Resolution of groin pain was demonstrated in 78.6% of patients in the cohort; however, those who did not have acetabular overhang had higher rates of success. The overall revision rate was 11.9%. US-CSI appears to be safe and effective in the diagnosis and treatment of iliopsoas tendonitis following primary THA. LEVEL OF EVIDENCE: Level IV, Therapeutic Study.
引用
- Weintraub MT, Barrack TN, Burnett RA, et al. Ultrasound-Guided Iliopsoas Bursal Injections for Management of Iliopsoas Bursitis After Total Hip Arthroplasty. J Arthroplasty. 2022. PMID: 36535438. doi:10.1016/j.arth.2022.12.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。